首页 > 最新文献

Drug design and delivery最新文献

英文 中文
In-silico drug design: An approach which revolutionarised the drug discovery process 计算机药物设计:一种彻底改变药物发现过程的方法
Pub Date : 2013-09-01 DOI: 10.13172/2054-4057-1-1-1119
Abdul Wadood, N. Ahmed, L. Shah, Ashfaq Ahmad, Hammad Hassan, Sulaiman Shams
Introduction Drug discovery and development is an intense, lengthy and an interdisciplinary venture. Recently, a trend towards the use of in-silico chemistry and molecular modelling for computer-aided drug design has gained significant momentum. Insilico drug design skills are used in nanotechnology, molecular biology, biochemistry etc. The main benefit of the in-silico drug design is cost effective in research and development of drugs. There are wide ranges of software that are used in in-silico drug design, Grid computing, window based general PBPK/PD modelling software, PKUDDS for structure based drug design, APIS, JAVA, Perl and Python, in-silico drug design as well as software including software libraries. There are different techniques used in in-silico drug design visualization, homology, molecular dynamic, energy minimization molecular docking and QSAR etc. In-silico drug design can take part considerably in all stages of drug development from the preclinical discovery stage to late stage clinical development. Its exploitation in drug development helps in the selection of only a potent lead molecule and may thus thwart the late stage clinical failures; thereby a major diminution in cost can be achieved. This article gives an insight into all the aspects of in-silico drug design; its potential, drivers, current development and the future prospects. Conclusion In-silico methods have been of great importance in target identification and in prediction of novel drugs. Introduction Drug discovery and development is a very complicated, time consuming process and there are many factors responsible for the failure of different drugs such as lack of effectiveness, side effects, poor pharmacokinetics, and marketable reasons. The expenditure of this process has amplified ominously during the past thirty-four years. The Pharmaceutical Manufacturer’s Association received the industry average reports which have shown that the expenditure of drug development has enlarged from $4 million in 1962 to over $350 million in 1996. The improvement time of a drug from the first synthesis to its foreword in the market, has almost multiplied between 1960 and 1980. It has kept on comparatively unaffected since 1980 with a present time period of 9-13 years.1,4 According to pharmaceutical research and manufacturers the estimated cost of the complete drug discovery process is about US$880 million and takes up to 14 years from initial research stage to the successful marketing of an new drug in 2001.4 The recent figures of DiMasi at the Tufts Centre for Study of Drug Development (CSDD) is about US$802 million spread over 12 years, which was reported in 2003,4 while the Boston Consulting Group estimates the cost as $880 million over 15 years. At present the cost involved in the drug discovery process ranges f rom $800 million to $1.8 billion,5 The establishment of the Computer-Aided Drug Design (CADD) Centre was to endorse joint research among the scientists of various f
药物的发现和开发是一个激烈的、漫长的、跨学科的冒险。最近,在计算机辅助药物设计中使用硅化学和分子模型的趋势已经获得了显著的势头。Insilico药物设计技术应用于纳米技术、分子生物学、生物化学等领域。计算机药物设计的主要优点是在药物研究和开发方面具有成本效益。有广泛的软件用于硅药物设计,网格计算,基于窗口的通用PBPK/PD建模软件,PKUDDS用于基于结构的药物设计,api, JAVA, Perl和Python,硅药物设计以及包括软件库在内的软件。在药物设计、可视化、同源性、分子动力学、能量最小化、分子对接和QSAR等方面有不同的技术应用。从临床前发现阶段到后期临床开发阶段,计算机药物设计可以在药物开发的各个阶段发挥重要作用。它在药物开发中的利用有助于只选择一个有效的先导分子,从而可能阻止晚期临床失败;这样就可以大大降低成本。这篇文章给出了一个洞察所有方面的硅药物设计;它的潜力、动力、发展现状和未来前景。结论计算机方法在新药的靶点鉴定和药物预测中具有重要的应用价值。药物的发现和开发是一个非常复杂、耗时的过程,导致不同药物失败的因素有很多,如缺乏有效性、副作用、药代动力学差和市场原因。这一进程的开支在过去34年里不祥地扩大了。药品制造商协会收到的行业平均报告显示,药物开发的支出已从1962年的400万美元增加到1996年的3.5亿美元以上。从1960年到1980年,一种药物从第一次合成到上市的改进时间几乎翻了一番。自1980年以来,它一直保持相对不受影响,目前的时间周期为9-13年。1 4根据药品研究与制造商完整的药物发现过程的估计成本大约是8.8亿美元,占到14年从最初研究阶段的成功的营销新药物在2001.4的最近的数据在塔夫茨DiMasi药物开发研究中心(CSDD)约8.02亿美元在12年,于2003年被报道,4日,波士顿咨询集团(Boston Consulting Group)估计,成本8.8亿美元超过15年。目前,药物研发过程所涉及的费用从8亿美元到18亿美元不等。计算机辅助药物设计中心的成立是为了支持生物学、生物物理学、结构生物学和计算科学家等不同领域的科学家进行联合研究CADDC申请的主要目标是启动这些伙伴关系,从而导致实施研究项目,以发现有可能转化为新治疗剂的新化合物。计算机药物设计是一个基础研究与实践相互结合、相互启发的广阔领域,QSAR/QSPR、基于结构的设计、组合文库设计、化学信息学、生物信息学等7种现代技术以及越来越多的生物和化学数据库被应用于该领域。此外,大量可用的工具为设计具有首选特异性的配体和抑制剂提供了非常成熟的基础本综述的目的是讨论芯片药物设计的过程。
{"title":"In-silico drug design: An approach which revolutionarised the drug discovery process","authors":"Abdul Wadood, N. Ahmed, L. Shah, Ashfaq Ahmad, Hammad Hassan, Sulaiman Shams","doi":"10.13172/2054-4057-1-1-1119","DOIUrl":"https://doi.org/10.13172/2054-4057-1-1-1119","url":null,"abstract":"Introduction Drug discovery and development is an intense, lengthy and an interdisciplinary venture. Recently, a trend towards the use of in-silico chemistry and molecular modelling for computer-aided drug design has gained significant momentum. Insilico drug design skills are used in nanotechnology, molecular biology, biochemistry etc. The main benefit of the in-silico drug design is cost effective in research and development of drugs. There are wide ranges of software that are used in in-silico drug design, Grid computing, window based general PBPK/PD modelling software, PKUDDS for structure based drug design, APIS, JAVA, Perl and Python, in-silico drug design as well as software including software libraries. There are different techniques used in in-silico drug design visualization, homology, molecular dynamic, energy minimization molecular docking and QSAR etc. In-silico drug design can take part considerably in all stages of drug development from the preclinical discovery stage to late stage clinical development. Its exploitation in drug development helps in the selection of only a potent lead molecule and may thus thwart the late stage clinical failures; thereby a major diminution in cost can be achieved. This article gives an insight into all the aspects of in-silico drug design; its potential, drivers, current development and the future prospects. Conclusion In-silico methods have been of great importance in target identification and in prediction of novel drugs. Introduction Drug discovery and development is a very complicated, time consuming process and there are many factors responsible for the failure of different drugs such as lack of effectiveness, side effects, poor pharmacokinetics, and marketable reasons. The expenditure of this process has amplified ominously during the past thirty-four years. The Pharmaceutical Manufacturer’s Association received the industry average reports which have shown that the expenditure of drug development has enlarged from $4 million in 1962 to over $350 million in 1996. The improvement time of a drug from the first synthesis to its foreword in the market, has almost multiplied between 1960 and 1980. It has kept on comparatively unaffected since 1980 with a present time period of 9-13 years.1,4 According to pharmaceutical research and manufacturers the estimated cost of the complete drug discovery process is about US$880 million and takes up to 14 years from initial research stage to the successful marketing of an new drug in 2001.4 The recent figures of DiMasi at the Tufts Centre for Study of Drug Development (CSDD) is about US$802 million spread over 12 years, which was reported in 2003,4 while the Boston Consulting Group estimates the cost as $880 million over 15 years. At present the cost involved in the drug discovery process ranges f rom $800 million to $1.8 billion,5 The establishment of the Computer-Aided Drug Design (CADD) Centre was to endorse joint research among the scientists of various f","PeriodicalId":11271,"journal":{"name":"Drug design and delivery","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78913798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 83
Microscopy characterisation of micro- and nanosystems for pharmaceutical use 医药用微纳米系统的显微表征
Pub Date : 2013-08-01 DOI: 10.13172/2054-4057-1-1-620
E. Esposito, M. Drechsler, R. Cortesi
technique for characterising microparticles and nanosystems recently developed by our research group. In particular, polyester or acrylic polymer microparticles for fenretinide administration are presented here. Moreover, with regard to nanosystems, solid lipid nanoparticles, nanostructured lipid carriers for prednisone and clotrimazole administration and monooleine aqueous dispersion are discussed. Methodology Microparticles were produced by the ‘solvent evaporation method’. Solid lipid nanoparticlesand nanostructured lipid carriers were prepared by stirring, followed by ultrasonication. Monooleine aqueous dispersionswere produced by the hydrotrope or by the hot homogenization methods. For scanning electron microscopyanalysis, microparticles were metallized by gold coating (Edwards Sputter coat-ing S150) and visualized at 15 – 20 kV with a 360 Stereoscan (Cambridge Instruments, Cambridge, UK). For Cryo-TEM ­analysis­ samples­were­ vitrified­ and­ transferred to a Zeiss EM922Omega (Zeiss SMT, Oberkochen, Germany). Images were recorded by a CCD digital camera (Ultrascan 1000, Gatan) and analyzed using a GMS 1.8 software (Gatan). Conclusion Microscopy is to be considered as an indispensable tool to study drug delivery systems. In particular, scanning electron microscopy is helpful in giving information about micro-sized powders, allowing to identify microspheres and microcapsules, as well as to obtain size distribution of the observed particles. Introduction Microand nanoparticles have attracted pharmaceutical interest in the last decades since they offer a number of advantages with respect to other delivery systems such as: (a) the ability to maintain unaltered physicochemical characteristics for long periods allowing long-term storage; (b) the possible administration through different ways (oral, intramuscular or subcutaneous) depending on their composition and (c) their suitability for industrial production1. Concerning nanosystems, lipid dispersions possess a potential use as matrixes able to dissolve and deliver active molecules in a controlled fashion, thereby improving their bioavailability and reducing side-effects2. In particular, solid lipid nanoparticles (SLN) are delivery systems in which the nano-dispersed phase has a matrix of crystalline solid lipids. SLN are able to protect encapsulated molecules from degradation and modulate their release3,4. Another generation of SLN is represented by nanostructured lipid carriers (NLC) whose matrix is composed of a mixture of solid–liquid lipids able to better solubilise lipophilic drugs5,6. Another type of lipid dispersion able to provide matrices for sustained­ drug­ release­ is­ typified­ by­ monooleine aqueous dispersions (MAD). MAD are heterogeneous systems generated by the dispersion of an amphiphilic lipid, such as monoolein, in water. They are constituted of complex lyotropic liquid crystalline nanostructures like micellar, lamellar, hexagonal and cubic phases, the predominance of one spe
我们研究小组最近开发的表征微粒和纳米系统的技术。特别地,聚酯或丙烯酸聚合物微粒芬维甲酸管理提出了这里。此外,关于纳米系统,固体脂质纳米颗粒,纳米结构的脂质载体强的松和氯霉唑给药和单油胺水分散进行了讨论。方法采用“溶剂蒸发法”制备微颗粒。采用搅拌法制备固体脂质纳米颗粒和纳米结构脂质载体。单油胺水分散体采用水相法或热均质法制备。为了进行扫描电子显微镜分析,用金涂层(Edwards溅射涂层S150)将微粒金属化,并在15 - 20 kV下用360度立体扫描仪(Cambridge Instruments, Cambridge, UK)进行可视化。用于低温透射电镜分析-样品-玻璃化-并转移到蔡司EM922Omega(蔡司SMT, Oberkochen,德国)。图像由CCD数码相机(Ultrascan 1000, Gatan)记录,并使用gms1.8软件(Gatan)进行分析。结论显微镜是研究给药系统不可缺少的工具。特别是,扫描电子显微镜有助于提供有关微尺寸粉末的信息,允许识别微球和微胶囊,以及获得所观察颗粒的尺寸分布。在过去的几十年里,微纳米颗粒已经引起了制药领域的兴趣,因为它们提供了一些相对于其他递送系统的优势,例如:(a)能够长时间保持不变的物理化学特性,允许长期储存;(b)根据其成分,可能通过不同方式(口服、肌肉注射或皮下注射)给药;(c)它们是否适合工业生产。在纳米系统中,脂质分散体作为基质具有潜在的用途,能够以可控的方式溶解和输送活性分子,从而提高其生物利用度并减少副作用2。特别是,固体脂质纳米颗粒(SLN)是一种输送系统,其中纳米分散相具有结晶固体脂质的基质。SLN能够保护被封装的分子免受降解并调节其释放3,4。另一代SLN以纳米结构脂质载体(NLC)为代表,其基质由固体-液体脂质混合物组成,能够更好地溶解亲脂性药物5,6。另一种能够为药物缓释提供基质的脂质分散体是单油碱水相分散体(MAD)。MAD是由两亲性脂质(如单油质)在水中分散而产生的非均相系统。它们是由胶束相、片层相、六方相和立方相等复杂的溶致液晶纳米结构组成的,其中一种比另一种更占优势。摘要:本文综述了使用显微镜作为表征微观和纳米颗粒系统形状和尺寸的工具的概况。在制药领域,显微技术的应用自微纳米技术出现以来发挥了重要作用。事实上,颗粒的形态及其内部结构确实会影响胶囊化药物的给药和释放方式。扫描电镜可以用来研究干粉的形貌。特别是由聚合物制成的微粒可以很好地可视化,并且可以测量它们的直径。通过在样品制备过程中切割粉末,可以获得有关微观结构内部形态的重要信息,区分胶囊或球体微观结构。低温透射电子显微镜是表征胶体系统的宝贵工具。特别是,可以很好地识别固体脂质纳米颗粒或溶性中间相等纳米颗粒系统的外部和内部形状。此外,还可以监测分散相的大小和分散体的整体结构。我们提供了关于使用电子显微镜的概述
{"title":"Microscopy characterisation of micro- and nanosystems for pharmaceutical use","authors":"E. Esposito, M. Drechsler, R. Cortesi","doi":"10.13172/2054-4057-1-1-620","DOIUrl":"https://doi.org/10.13172/2054-4057-1-1-620","url":null,"abstract":"technique for characterising microparticles and nanosystems recently developed by our research group. In particular, polyester or acrylic polymer microparticles for fenretinide administration are presented here. Moreover, with regard to nanosystems, solid lipid nanoparticles, nanostructured lipid carriers for prednisone and clotrimazole administration and monooleine aqueous dispersion are discussed. Methodology Microparticles were produced by the ‘solvent evaporation method’. Solid lipid nanoparticlesand nanostructured lipid carriers were prepared by stirring, followed by ultrasonication. Monooleine aqueous dispersionswere produced by the hydrotrope or by the hot homogenization methods. For scanning electron microscopyanalysis, microparticles were metallized by gold coating (Edwards Sputter coat-ing S150) and visualized at 15 – 20 kV with a 360 Stereoscan (Cambridge Instruments, Cambridge, UK). For Cryo-TEM ­analysis­ samples­were­ vitrified­ and­ transferred to a Zeiss EM922Omega (Zeiss SMT, Oberkochen, Germany). Images were recorded by a CCD digital camera (Ultrascan 1000, Gatan) and analyzed using a GMS 1.8 software (Gatan). Conclusion Microscopy is to be considered as an indispensable tool to study drug delivery systems. In particular, scanning electron microscopy is helpful in giving information about micro-sized powders, allowing to identify microspheres and microcapsules, as well as to obtain size distribution of the observed particles. Introduction Microand nanoparticles have attracted pharmaceutical interest in the last decades since they offer a number of advantages with respect to other delivery systems such as: (a) the ability to maintain unaltered physicochemical characteristics for long periods allowing long-term storage; (b) the possible administration through different ways (oral, intramuscular or subcutaneous) depending on their composition and (c) their suitability for industrial production1. Concerning nanosystems, lipid dispersions possess a potential use as matrixes able to dissolve and deliver active molecules in a controlled fashion, thereby improving their bioavailability and reducing side-effects2. In particular, solid lipid nanoparticles (SLN) are delivery systems in which the nano-dispersed phase has a matrix of crystalline solid lipids. SLN are able to protect encapsulated molecules from degradation and modulate their release3,4. Another generation of SLN is represented by nanostructured lipid carriers (NLC) whose matrix is composed of a mixture of solid–liquid lipids able to better solubilise lipophilic drugs5,6. Another type of lipid dispersion able to provide matrices for sustained­ drug­ release­ is­ typified­ by­ monooleine aqueous dispersions (MAD). MAD are heterogeneous systems generated by the dispersion of an amphiphilic lipid, such as monoolein, in water. They are constituted of complex lyotropic liquid crystalline nanostructures like micellar, lamellar, hexagonal and cubic phases, the predominance of one spe","PeriodicalId":11271,"journal":{"name":"Drug design and delivery","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79227113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Insoluble drug delivery technologies: review of health benefits and business potentials 不溶性给药技术:健康效益和商业潜力综述
Pub Date : 2013-08-01 DOI: 10.13172/2054-4057-1-1-619
B. Siddalingappa, V. Nekkanti, G. Betageri
section 505(b)(2) 2 . The majority of those NDA’s under this section are new formulations. New dosage form, change of forms of drugs (Ester/salt), prodrug/active metabolite of drug and different route of administration are the few changes that the pharmaceutical companies are exploring for 505(b)(2) fillings 3 . The insoluble drugs are being reformulated. Hence this review summarises various solubilisation technologies and their commercial and health benefits. This review discusses drug formulations approved exploring different solubilisation technologies with insight to health benefits and commercial profits.
第505(b)(2)条本节下的大部分保密协议都是新的配方。505(b)(2)填充物的新剂型、药物形态(酯/盐)的变化、药物的前药/活性代谢物以及不同给药途径是制药公司正在探索的少数变化。不溶性药物正在重新配制。因此,本文综述了各种增溶技术及其商业和健康效益。这篇综述讨论了药物制剂批准探索不同的增溶技术与洞察健康效益和商业利润。
{"title":"Insoluble drug delivery technologies: review of health benefits and business potentials","authors":"B. Siddalingappa, V. Nekkanti, G. Betageri","doi":"10.13172/2054-4057-1-1-619","DOIUrl":"https://doi.org/10.13172/2054-4057-1-1-619","url":null,"abstract":"section 505(b)(2) 2 . The majority of those NDA’s under this section are new formulations. New dosage form, change of forms of drugs (Ester/salt), prodrug/active metabolite of drug and different route of administration are the few changes that the pharmaceutical companies are exploring for 505(b)(2) fillings 3 . The insoluble drugs are being reformulated. Hence this review summarises various solubilisation technologies and their commercial and health benefits. This review discusses drug formulations approved exploring different solubilisation technologies with insight to health benefits and commercial profits.","PeriodicalId":11271,"journal":{"name":"Drug design and delivery","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75568546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Synthesis of the diastereomers of 5-(2,2-dichlorocyclopropyl)- and 5-(2-chlorocyclopropyl)-2'-deoxyuridine, and the antiviral and cytotoxic activity of these and bromo analogues. 5-(2,2-二氯环丙基)-和5-(2-氯环丙基)-2'-脱氧尿苷非对映体的合成及其与溴类似物的抗病毒和细胞毒活性。
Pub Date : 1991-07-01
M Tandon, S Singh, L I Wiebe, E E Knaus, W P Gati, M L Tempest

Syntheses of the two diastereomers (5a and 6a) of 5-(2,2-dichlorocyclopropyl)-, and of the four diastereomers (7a-10a) of 5-(2-chlorocyclopropyl)-2'-deoxyuridine are described. These, and corresponding diastereomers (5b and 6b; 7b-10b) of 5-(2,2-dibromocyclopropyl)- and 5-(2-bromocyclopropyl)-2'-deoxyuridine (prepared in an earlier investigation) were examined for antiviral and cytotoxic activity, in comparison with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and 5-fluoro-2'-deoxyuridine (FDU). 5-[(1R,2R)-2-Chlorocyclopropyl]-2'-deoxyuridine (9a) was the most active antiviral agent (IC50 = 25 micrograms/ml) against herpes simplex virus type 1 (HSV-1) relative to BVDU (IC50 = 0.082 microgram/ml). Compounds having the R configuration at the C-1 and/or C-2 positions of the 5-[2,2-dichloro(or 2-chloro)cyclopropyl] substituent exhibited the most potent antiviral activity. The cytotoxic activities of the 5-(2,2-dihalocyclopropyl)- (5-6a and b) and 5-(2-halocyclopropyl)- diastereomers (7-10a and b) were dependent upon both the configuration of the C-1 and/or C-2 cyclopropyl carbons and the nature of the halogeno (Cl, Br) substituent. 5-[(1R)-2,2-Dichlorocyclopropyl]-2'-deoxyuridine (6a) was the most active cytotoxic compound in the CCRF-CEM (IC50 = 17 microM) and HL-60 (IC50 = 64 microM) screens relative to FDU, which exhibited IC50 values of 4.7 x 10(-3) and 77 microM in these respective screens.

描述了5-(2,2-二氯环丙基)-的两个非对映体(5a和6a)和5-(2-氯环丙基)-2'-脱氧尿苷的四个非对映体(7a-10a)的合成。这些,以及相应的非对映体(5b和6b;与(E)-5-(2-溴环丙基)-2'-脱氧尿苷(BVDU)和5-(2-溴环丙基)-2'-脱氧尿苷(FDU)相比,研究了7b-10b)的5-(2,2-二溴环丙基)-和5-氟-2'-脱氧尿苷(FDU)的抗病毒和细胞毒性活性。5-[(1R,2R)-2-氯环丙基]-2′-脱氧尿苷(9a)对单纯疱疹病毒1型(HSV-1)的抗病毒活性最高(IC50 = 25微克/ml),相对于BVDU (IC50 = 0.082微克/ml)。在5-[2,2-二氯(或2-氯)环丙基]取代基的C-1和/或C-2位置上具有R构型的化合物表现出最有效的抗病毒活性。5-(2,2-二卤代环丙基)- (5-6a和b)和5-(2-卤代环丙基)-非对映体(7-10a和b)的细胞毒性活性取决于C-1和/或C-2环丙基碳的构型和卤代(Cl, Br)取代基的性质。5-[(1R)-2,2-二氯环丙基]-2′-脱氧尿苷(6a)是CCRF-CEM (IC50 = 17微米)和HL-60 (IC50 = 64微米)筛选中相对于FDU最具活性的细胞毒化合物,其IC50值分别为4.7 × 10(-3)和77微米。
{"title":"Synthesis of the diastereomers of 5-(2,2-dichlorocyclopropyl)- and 5-(2-chlorocyclopropyl)-2'-deoxyuridine, and the antiviral and cytotoxic activity of these and bromo analogues.","authors":"M Tandon,&nbsp;S Singh,&nbsp;L I Wiebe,&nbsp;E E Knaus,&nbsp;W P Gati,&nbsp;M L Tempest","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Syntheses of the two diastereomers (5a and 6a) of 5-(2,2-dichlorocyclopropyl)-, and of the four diastereomers (7a-10a) of 5-(2-chlorocyclopropyl)-2'-deoxyuridine are described. These, and corresponding diastereomers (5b and 6b; 7b-10b) of 5-(2,2-dibromocyclopropyl)- and 5-(2-bromocyclopropyl)-2'-deoxyuridine (prepared in an earlier investigation) were examined for antiviral and cytotoxic activity, in comparison with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and 5-fluoro-2'-deoxyuridine (FDU). 5-[(1R,2R)-2-Chlorocyclopropyl]-2'-deoxyuridine (9a) was the most active antiviral agent (IC50 = 25 micrograms/ml) against herpes simplex virus type 1 (HSV-1) relative to BVDU (IC50 = 0.082 microgram/ml). Compounds having the R configuration at the C-1 and/or C-2 positions of the 5-[2,2-dichloro(or 2-chloro)cyclopropyl] substituent exhibited the most potent antiviral activity. The cytotoxic activities of the 5-(2,2-dihalocyclopropyl)- (5-6a and b) and 5-(2-halocyclopropyl)- diastereomers (7-10a and b) were dependent upon both the configuration of the C-1 and/or C-2 cyclopropyl carbons and the nature of the halogeno (Cl, Br) substituent. 5-[(1R)-2,2-Dichlorocyclopropyl]-2'-deoxyuridine (6a) was the most active cytotoxic compound in the CCRF-CEM (IC50 = 17 microM) and HL-60 (IC50 = 64 microM) screens relative to FDU, which exhibited IC50 values of 4.7 x 10(-3) and 77 microM in these respective screens.</p>","PeriodicalId":11271,"journal":{"name":"Drug design and delivery","volume":"7 4","pages":"295-307"},"PeriodicalIF":0.0,"publicationDate":"1991-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12822351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The use of micronized cellulose disintegrants as insoluble swellable matrices for sustained-release tablets. 用微粉纤维素崩解剂作为缓释片的不溶性溶胀基质。
Pub Date : 1991-07-01
H Nakagami, M Nada

Five cellulose disintegrants--low-substituted hydroxypropylcellulose (L-HPC), microcrystalline cellulose (MCC), carboxymethylcellulose (CMC), cross-linked NaCMC (C.L.NaCMC), and CaCMC-were evaluated as directly compressed matrices for sustained-release (SR) tablets in vitro, using procainamide hydrochloride as a model drug. Coarser particles (14-19 microns) of the jet mill ground disintegrants, as well as intact disintegrants, provided rapidly disintegrating tablets with fast drug release but finer particles (2.5-3.5 microns) provided matrix-type SR tablets. The SR tablets based on non-ionic polymers (L-HPC and MCC) did not disintegrate at any pH; those based on anionic polymers (C.L.NaCMC and CaCMC) did not disintegrate at pH 1.2, but they disintegrated gradually from the exterior in water and in a pH 6.8 medium. We conclude that the particle size and concentration of the cellulose disintegrants are determinant factors in the formulation of SR matrices.

以盐酸普鲁卡因酰胺为模型药物,对低取代羟丙基纤维素(L-HPC)、微晶纤维素(MCC)、羧甲基纤维素(CMC)、交联NaCMC (C.L.NaCMC)和cacmc这5种纤维素崩解剂作为直接压缩基质用于体外缓释片(SR)的评价。射流磨碎崩解剂颗粒粗(14 ~ 19微米)和完整崩解剂颗粒细(2.5 ~ 3.5微米),崩解片剂快速释放,基质型SR片剂快速释放。基于非离子聚合物(L-HPC和MCC)的SR片在任何pH下均不崩解;阴离子聚合物(c.l.c acmc和CaCMC)在pH为1.2时不发生分解,但在水和pH为6.8的介质中从外部逐渐分解。我们得出结论,纤维素崩解剂的粒径和浓度是SR基质配方的决定因素。
{"title":"The use of micronized cellulose disintegrants as insoluble swellable matrices for sustained-release tablets.","authors":"H Nakagami,&nbsp;M Nada","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Five cellulose disintegrants--low-substituted hydroxypropylcellulose (L-HPC), microcrystalline cellulose (MCC), carboxymethylcellulose (CMC), cross-linked NaCMC (C.L.NaCMC), and CaCMC-were evaluated as directly compressed matrices for sustained-release (SR) tablets in vitro, using procainamide hydrochloride as a model drug. Coarser particles (14-19 microns) of the jet mill ground disintegrants, as well as intact disintegrants, provided rapidly disintegrating tablets with fast drug release but finer particles (2.5-3.5 microns) provided matrix-type SR tablets. The SR tablets based on non-ionic polymers (L-HPC and MCC) did not disintegrate at any pH; those based on anionic polymers (C.L.NaCMC and CaCMC) did not disintegrate at pH 1.2, but they disintegrated gradually from the exterior in water and in a pH 6.8 medium. We conclude that the particle size and concentration of the cellulose disintegrants are determinant factors in the formulation of SR matrices.</p>","PeriodicalId":11271,"journal":{"name":"Drug design and delivery","volume":"7 4","pages":"321-32"},"PeriodicalIF":0.0,"publicationDate":"1991-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13088838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibition of cholesterol side-chain cleavage. Part 5. Synthesis of 22-(p-chlorophenyl) cholesterol analogues. 抑制胆固醇侧链切割。第5部分。22-(对氯苯基)胆固醇类似物的合成。
Pub Date : 1991-07-01
C P Bergstrom, R Clarke, J F Fitzloff, M C Lu

Three 22-(p-chloroaryl) analogues of cholesterol (6a-c) were synthesized and evaluated as potential inhibitors of the adrenal cholesterol side-chain cleavage enzyme, in comparison with the known 20-aryl analogue, 20-(p-chlorophenyl)-5-prenen-3 beta,20-diol (2b). All were potent inhibitors. An oxygen at C-22 (analogues 6a and 6b) enhanced the strong binding to the enzyme. Two compounds (6b and 6c) are potential substrates of the enzyme. Possible pharmaceutical uses for these compounds and their derivatives are discussed.

合成了3个22-(对氯芳基)胆固醇类似物(6a-c),并与已知的20-芳基类似物20-(对氯苯基)-5-丙烯-3 β,20-二醇(2b)进行了比较,评估了它们作为肾上腺胆固醇侧链裂解酶的潜在抑制剂。它们都是有效的抑制剂。C-22上的氧(类似物6a和6b)增强了与酶的强结合。两种化合物(6b和6c)是该酶的潜在底物。讨论了这些化合物及其衍生物可能的医药用途。
{"title":"Inhibition of cholesterol side-chain cleavage. Part 5. Synthesis of 22-(p-chlorophenyl) cholesterol analogues.","authors":"C P Bergstrom,&nbsp;R Clarke,&nbsp;J F Fitzloff,&nbsp;M C Lu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Three 22-(p-chloroaryl) analogues of cholesterol (6a-c) were synthesized and evaluated as potential inhibitors of the adrenal cholesterol side-chain cleavage enzyme, in comparison with the known 20-aryl analogue, 20-(p-chlorophenyl)-5-prenen-3 beta,20-diol (2b). All were potent inhibitors. An oxygen at C-22 (analogues 6a and 6b) enhanced the strong binding to the enzyme. Two compounds (6b and 6c) are potential substrates of the enzyme. Possible pharmaceutical uses for these compounds and their derivatives are discussed.</p>","PeriodicalId":11271,"journal":{"name":"Drug design and delivery","volume":"7 4","pages":"259-68"},"PeriodicalIF":0.0,"publicationDate":"1991-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13088834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis and anticonvulsant activity of 3-(3'-trifluoromethylphenoxy)-pyridines and -dihydropyridines. 3-(3'-三氟甲基苯氧基)-吡啶和-二氢吡啶的合成及抗惊厥活性。
Pub Date : 1991-07-01
O A Phillips, E E Knaus

3-(3"Trifluoromethylphenoxy)-1,4-dihydropyridines containing phenoxycarbonyl, methoxycarbonyl or acetyl at the 1 position, and phenyl, n-butyl or methyl at the 4-position were synthesised (generalised structure 4). Four members of this series (4a-c, 4g)--the rest were not evaluated because of their facile oxidation to pyridines--were found to be inactive in maximal electroschock (MES) and subcutaneous pentylenetetrazole (scPTZ) screening tests in mice, suggesting that the 1-carbonyl-3-(3'-trifluoromethyl-phenoxyl)-1,4-dihydropyridyl++ + moiety is not a suitable anticonvulsant pharmacophore. 4-Phenyl-3-(3'-trifluoromethylphenoxy)pyridine (5a)--the oxidation product of 4a--was also inactive in both tests. In contrast, the isomeric 2-phenyl-3-(3'-trifluoromethylphenoxy)pyridine (7), whilst inactive in the scPTZ test, exhibited significant anticonvulsant activity in the mouse MES test (intraperitoneal administration; ED50 = 159 mg/kg), and increased activity following its oral administration in a rat MES test (ED50 = 31.9 mg/kg). It caused displacement of 10 microM [3H]flunitrazepam from mouse whole brain P2 pellets at 30 microM concentration, indicating low affinity for the benzodiazepine receptor(s).

合成了3-(3"三氟甲基苯氧基)-1,4-二氢吡啶,在1位含有苯氧羰基、甲氧羰基或乙酰基,在4位含有苯基、正丁基或甲基(一般结构4)。该系列的四个成员(4a-c, 4g)——其余的没有被评估,因为它们容易氧化成吡啶——在小鼠的最大电击(MES)和皮下戊四唑(scPTZ)筛选试验中被发现无活性。提示1-羰基-3-(3′-三氟甲基-苯氧基)-1,4-二氢吡啶基++ +部分不是合适的抗惊厥药效团。4-苯基-3-(3'-三氟甲基苯氧基)吡啶(5a)——4a的氧化产物——在两项试验中也没有活性。相反,异构体2-苯基-3-(3′-三氟甲基苯氧基)吡啶(7)虽然在scPTZ试验中无活性,但在小鼠MES试验中表现出显著的抗惊厥活性(腹腔给药;ED50 = 159 mg/kg),在大鼠MES试验中口服后活性增加(ED50 = 31.9 mg/kg)。在30 μ m浓度下,氟硝西泮从小鼠全脑P2微丸中移位10 μ m [3H],表明其对苯二氮卓类受体的亲和力较低。
{"title":"Synthesis and anticonvulsant activity of 3-(3'-trifluoromethylphenoxy)-pyridines and -dihydropyridines.","authors":"O A Phillips,&nbsp;E E Knaus","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>3-(3\"Trifluoromethylphenoxy)-1,4-dihydropyridines containing phenoxycarbonyl, methoxycarbonyl or acetyl at the 1 position, and phenyl, n-butyl or methyl at the 4-position were synthesised (generalised structure 4). Four members of this series (4a-c, 4g)--the rest were not evaluated because of their facile oxidation to pyridines--were found to be inactive in maximal electroschock (MES) and subcutaneous pentylenetetrazole (scPTZ) screening tests in mice, suggesting that the 1-carbonyl-3-(3'-trifluoromethyl-phenoxyl)-1,4-dihydropyridyl++ + moiety is not a suitable anticonvulsant pharmacophore. 4-Phenyl-3-(3'-trifluoromethylphenoxy)pyridine (5a)--the oxidation product of 4a--was also inactive in both tests. In contrast, the isomeric 2-phenyl-3-(3'-trifluoromethylphenoxy)pyridine (7), whilst inactive in the scPTZ test, exhibited significant anticonvulsant activity in the mouse MES test (intraperitoneal administration; ED50 = 159 mg/kg), and increased activity following its oral administration in a rat MES test (ED50 = 31.9 mg/kg). It caused displacement of 10 microM [3H]flunitrazepam from mouse whole brain P2 pellets at 30 microM concentration, indicating low affinity for the benzodiazepine receptor(s).</p>","PeriodicalId":11271,"journal":{"name":"Drug design and delivery","volume":"7 4","pages":"279-86"},"PeriodicalIF":0.0,"publicationDate":"1991-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12822350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis and anti-inflammatory activity of 5-(1,4-dihydropyridyl)-tetrazol-2-acetic acids, esters and amides. 5-(1,4-二氢吡啶基)-四唑-2-乙酸、酯和酰胺的合成及其抗炎活性
Pub Date : 1991-07-01
P Kumar, E E Knaus

Thirteen 5-[3-(1,4-dihydropyridyl)]-2H-tetrazol-2-acetic acids (18-30), seventeen esters (4-17, 32, 35, 41) and eight amides (31, 32-34, 36-40) were synthesized in order to investigate the effect of alpha-substituents (R1 = H, Me) and 1,4-dihydropyridyl substituents (R2 = aryl, alkyl; R3 = phenoxy, methoxy or amino) on anti-inflammatory activity. The effects of the R1, R2 or R3-substituents were variable but highly interdependent. The relative order of anti-inflammatory potency was generally acid greater than amide and ester. Methyl 2-methyl-2-(5-[3-(4-phenyl-1-carbamoyl-1,4-dihydropyridyl)]-2H- tetrazol-2-yl) acetate (35) was the most effective anti-inflammatory agent in the group, reducing inflammation 96% at 5 hr after a 50 mg/kg po dose, relative to ibuprofen's 52% inhibition at 5 hr after a 100 mg/kg po dose.

合成了13个5-[3-(1,4-二氢吡啶基)]- 2h -四唑-2-乙酸(18-30),17个酯(4- 17,32,35,41)和8个酰胺(31,32 - 34,36 -40),考察了α取代基(R1 = H, Me)和1,4-二氢吡啶基取代基(R2 =芳基,烷基;R3 =苯氧基,甲氧基或氨基)抗炎活性。R1, R2或r3取代基的影响是可变的,但高度相互依赖。抗炎效力的相对顺序一般为酸类强于酰胺类和酯类。2-甲基-2-(5-[3-(4-苯基-1-氨基甲酰-1,4-二氢吡啶基)]- 2h -四唑-2-基)乙酸甲酯(35)是组中最有效的抗炎药,在50 mg/kg po剂量后5小时炎症减少96%,而布洛芬在100 mg/kg po剂量后5小时的抑制作用为52%。
{"title":"Synthesis and anti-inflammatory activity of 5-(1,4-dihydropyridyl)-tetrazol-2-acetic acids, esters and amides.","authors":"P Kumar,&nbsp;E E Knaus","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Thirteen 5-[3-(1,4-dihydropyridyl)]-2H-tetrazol-2-acetic acids (18-30), seventeen esters (4-17, 32, 35, 41) and eight amides (31, 32-34, 36-40) were synthesized in order to investigate the effect of alpha-substituents (R1 = H, Me) and 1,4-dihydropyridyl substituents (R2 = aryl, alkyl; R3 = phenoxy, methoxy or amino) on anti-inflammatory activity. The effects of the R1, R2 or R3-substituents were variable but highly interdependent. The relative order of anti-inflammatory potency was generally acid greater than amide and ester. Methyl 2-methyl-2-(5-[3-(4-phenyl-1-carbamoyl-1,4-dihydropyridyl)]-2H- tetrazol-2-yl) acetate (35) was the most effective anti-inflammatory agent in the group, reducing inflammation 96% at 5 hr after a 50 mg/kg po dose, relative to ibuprofen's 52% inhibition at 5 hr after a 100 mg/kg po dose.</p>","PeriodicalId":11271,"journal":{"name":"Drug design and delivery","volume":"7 4","pages":"287-94"},"PeriodicalIF":0.0,"publicationDate":"1991-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13088836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular modification of anticholinergics as probes for muscarinic receptors. Part 4. Ileal selective muscarinic antagonists. 抗胆碱能药物作为毒蕈碱受体探针的分子修饰。第4部分。回肠选择性毒蕈碱拮抗剂。
Pub Date : 1991-07-01
M C Lu, G D Noble, E B Thompson, S M Vogel

Systematic studies of the structure-activity relationships of atropine-like anticholinergic drugs have provided valuable information about the nature of the muscarinic receptor. In this study, the pharmacological activities of the (Z) and (E)-isomers of 2-phenylcyclohexyl diethylaminoethyl ether (1 and 2, respectively) in the isolated rat left atrium were investigated and compared with their activities in the isolated rat ileum preparation. Compound 1 was found to be one of the most ileal selective muscarinic antagonists reported to date. Other data concerning possible differences in the receptor-bound conformations of tropate- versus benzilate-derived muscarinic antagonists are also presented.

对阿托品样抗胆碱能药物构效关系的系统研究为毒蕈碱受体的性质提供了有价值的信息。本研究研究了2-苯基环己基二乙基氨基乙醚(Z)和(E)-异构体(1和2)在离体大鼠左心房的药理活性,并与它们在离体大鼠回肠制剂中的活性进行了比较。化合物1是迄今为止报道的最具回肠选择性的毒蕈碱拮抗剂之一。关于托托酸盐与苯磺酸盐衍生毒蕈碱拮抗剂受体结合构象可能存在差异的其他数据也被提出。
{"title":"Molecular modification of anticholinergics as probes for muscarinic receptors. Part 4. Ileal selective muscarinic antagonists.","authors":"M C Lu,&nbsp;G D Noble,&nbsp;E B Thompson,&nbsp;S M Vogel","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Systematic studies of the structure-activity relationships of atropine-like anticholinergic drugs have provided valuable information about the nature of the muscarinic receptor. In this study, the pharmacological activities of the (Z) and (E)-isomers of 2-phenylcyclohexyl diethylaminoethyl ether (1 and 2, respectively) in the isolated rat left atrium were investigated and compared with their activities in the isolated rat ileum preparation. Compound 1 was found to be one of the most ileal selective muscarinic antagonists reported to date. Other data concerning possible differences in the receptor-bound conformations of tropate- versus benzilate-derived muscarinic antagonists are also presented.</p>","PeriodicalId":11271,"journal":{"name":"Drug design and delivery","volume":"7 4","pages":"269-78"},"PeriodicalIF":0.0,"publicationDate":"1991-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13088835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prolongation of drug release by covalent bonding of drugs to serum albumin microbeads. 通过药物与血清白蛋白微珠的共价键作用延长药物释放。
Pub Date : 1991-07-01
M T Sheu, C H Liu, T D Sokoloski

Reaction conditions for the covalent bonding of 5'-deoxy-5-fluorouridine to serum albumin microbeads by means of a water-soluble carbodiimide were studied. Optimum coupling of dFUR to the microbeads occurred when pure water was used as solvent. There was no significant difference in the bonding efficiency for microbeads prepared at different stirring speeds, and there was a limit to the amount of dFUR that could be bound with increasing reaction time. Yields were low possibly because of competing coupling reactions involving carbodiimide and other reactive groups in the protein. The release of dFUR from dFUR-bound microbeads was slow and biexponential. The fraction of dFUR bound in the interior of the microbeads increased with increasing reaction time.

以水溶性碳二亚胺为载体,研究了5′-脱氧-5-氟吡啶与血清白蛋白微珠共价键的反应条件。以纯水为溶剂时,dFUR与微球的耦合效果最佳。不同搅拌速度下制备的微珠的结合效率无显著差异,随着反应时间的延长,dFUR的结合量有一定的限制。产率低可能是由于蛋白质中碳二亚胺和其他活性基团的偶联反应。从dFUR结合的微球中释放dFUR是缓慢的双指数释放。随着反应时间的延长,dFUR在微珠内部结合的比例增加。
{"title":"Prolongation of drug release by covalent bonding of drugs to serum albumin microbeads.","authors":"M T Sheu,&nbsp;C H Liu,&nbsp;T D Sokoloski","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Reaction conditions for the covalent bonding of 5'-deoxy-5-fluorouridine to serum albumin microbeads by means of a water-soluble carbodiimide were studied. Optimum coupling of dFUR to the microbeads occurred when pure water was used as solvent. There was no significant difference in the bonding efficiency for microbeads prepared at different stirring speeds, and there was a limit to the amount of dFUR that could be bound with increasing reaction time. Yields were low possibly because of competing coupling reactions involving carbodiimide and other reactive groups in the protein. The release of dFUR from dFUR-bound microbeads was slow and biexponential. The fraction of dFUR bound in the interior of the microbeads increased with increasing reaction time.</p>","PeriodicalId":11271,"journal":{"name":"Drug design and delivery","volume":"7 4","pages":"251-7"},"PeriodicalIF":0.0,"publicationDate":"1991-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12995600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Drug design and delivery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1